BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, announced that its strategic distribution and licensing agreement with Electrome Corporation has officially moved into the execution phase, with manufacturing now underway for the launch of BioElectronics’ flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform. The partnership marks a major milestone as Electrome prepares an aggressive consumer launch strategy designed to accelerate awareness and adoption of drug-free pain therapy technologies across North America.
Electrome is building a comprehensive AI-native pain management platform that integrates advanced artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. This system is intended to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions. Under the agreement, Electrome will market and distribute BioElectronics’ FDA-cleared pulsed shortwave therapy products, including ActiPatch and additional products within the BioElectronics portfolio.
“We are excited to officially begin the commercial phase of this relationship with Electrome,” said Kelly Whelan, President of BioElectronics Corporation. “The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth.”
Electrome’s planned rollout will focus heavily on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems designed to streamline the consumer purchasing experience while increasing awareness of non-drug pain management solutions. “This is an exciting moment for both organizations,” said Ken Mayer, CEO of Electrome Corporation. “We believe BioElectronics’ technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption.”
BioElectronics’ pulsed shortwave therapy technology is designed to provide drug-free, non-invasive pain relief through a wearable therapy platform cleared by the U.S. FDA for the adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures. Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.
The implications of this announcement are significant for the pain management industry, as the partnership leverages AI to drive consumer adoption of non-pharmaceutical alternatives amid growing concerns over opioid dependency and side effects of conventional pain medications. For business leaders, this signals a shift toward technology-enabled healthcare commercialization, where AI and digital marketing are used to scale innovative medical products directly to consumers. The success of this rollout could pave the way for similar partnerships, accelerating the market for drug-free pain solutions and reshaping how consumers access and choose pain management therapies.
